CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

City of Edinburgh, United Kingdom

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis

    To compare the safety of Test, Reference, and Placebo treatments in patients with Plaque Psoriasis. Patients in this randomized, double-blind, three-arm, placebo controlled, parallel-design, multi-site study will be randomly assigned in a 2:2:1 ratio to treatment with the test product, reference product or placebo control, respectively.

    Phase

    3

    Span

    50 weeks

    Sponsor

    Teva Pharmaceuticals USA

    Louisville, Kentucky

    Recruiting

    Healthy Volunteers

  • A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

    This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.

    Phase

    3

    Span

    147 weeks

    Sponsor

    Celldex Therapeutics

    Louisville, Kentucky

    Recruiting

  • A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

    Phase

    3

    Span

    97 weeks

    Sponsor

    Alumis Inc

    Louisville, Kentucky

    Recruiting

  • A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.

    Phase

    2

    Span

    87 weeks

    Sponsor

    Vyne Therapeutics Inc.

    Louisville, Kentucky

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

    Phase

    3

    Span

    109 weeks

    Sponsor

    MoonLake Immunotherapeutics AG

    Louisville, Kentucky

    Recruiting

  • A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

    Phase

    N/A

    Span

    504 weeks

    Sponsor

    argenx

    Louisville, Kentucky

    Recruiting

  • Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

    Phase

    3

    Span

    298 weeks

    Sponsor

    Shanghai Junshi Bioscience Co., Ltd.

    Louisville, Kentucky

    Recruiting

  • CERENOVUS Neurothrombectomy Devices Registry

    The objective of this study are to separately assess the effectiveness of the CERENOVUS neurothrombectomy devices (EmboTrap® Revascularization Device, and Large Bore Catheter/EMBOVAC Aspiration Catheter) in a real-world setting, as well as to explore correlations between patient comorbidities, clot characteristics, revascularization rates, and clinical outcomes..

    Phase

    N/A

    Span

    314 weeks

    Sponsor

    Cerenovus, Part of DePuy Synthes Products, Inc.

    Louisville, Kentucky

    Recruiting

  • Safety and Efficacy of VDPHL01 in Males With AGA

    Phase

    3

    Span

    90 weeks

    Sponsor

    Veradermics, Inc.

    Louisville, Kentucky

    Recruiting

  • Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

    Phase

    N/A

    Span

    289 weeks

    Sponsor

    University of Michigan

    Louisville, Kentucky

    Recruiting

1-10 of 52
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information